The 2021 MOBILE randomised controlled trial (RCT), recruited individuals with T2DM on basal insulin (n = 175), and showed that using CGM for an 8‐month period was associated with significantly reduced HbA1c, lower time above range (TAR) in hyperglycaemia >13.9 mmol/L (250 mg/dL) and reduced rates of hypoglycaemia events, compared with a control group using self‐monitored blood glucose (SMBG) testing alone.17 This evidence concerns the gene INS and Hypoglycemia.